Document is current
Any future updates will be listed below
-
Authors
Lazzaro, Carlo https://orcid.org/0000-0003-4795-1834
Bergamaschi, Roberto https://orcid.org/0000-0002-1397-511X
Zaffaroni, Mauro https://orcid.org/0000-0001-9020-934X
Totaro, Rocco https://orcid.org/0000-0001-5852-7743
Paolicelli, Damiano https://orcid.org/0000-0002-8645-1763
- License Information
-
More Information
Article History
Received: 27 May 2024
Accepted: 19 September 2024
First Online: 21 January 2025
Declarations
:
: This contribution was exempt from ethical review due to it being a Commentary.
: Authors declare no conflicts of interest/competing interests with this Commentary. CL has received teaching fees from University of Pavia, research grants, speaker or consultancy fees from argenx BV, AstraZeneca S.p.A, Ipsen S.p.A., Janssen-Cilag SPA, Horizon Therapeutics srl, Roche S.p.A., Roche Diagnostics S.p.A., Sanofi s.r.l., Santen GmbH, Santen Italy S.R.L. RB has served on scientific advisory boards for Biogen, Merck-Serono, Novartis, Sanofi-Genzyme; received research support from Almirall, Bayer, Biogen, Merck-Serono, Novartis, Sanofi-Genzyme; received support for travel and congress from Biogen, Roche, Merck-Serono, Sanofi-Genzyme, Teva; received honoraria for speaking engagement from Biogen, Merck-Serono, Novartis, Sanofi-Genzyme. MZ has served on scientific advisory boards and received honoraria for speaking or support for travel and congress attendance from Almirall, Biogen, Merck-Serono, Novartis, Sanofi-Genzyme. RT has received speaker or consultancy fees from Biogen, Merck-Serono, Novartis, Roche, Sanofi and Teva. DP has received honoraria for consultancy and/or speaking from Biogen Idec, Merck-Serono, Bayer-Schering, Sanofi-Aventis, TEVA, Novartis and Genzyme.
: Authors declare that no section of this Commentary was supported by Artificial Intelligence.
